Document Detail


Treatment of neuroblastoma with human natural antibodies.
MedLine Citation:
PMID:  18558369     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Serum of healthy individuals may contain natural antibodies which are able to induce complement dependent cytotoxicity against neuroblastoma. The prevalence of cytotoxic activity in serum of neuroblastoma patients is low compared with age matched healthy children which indicates a role of natural cytotoxic antibodies in immunosurveillance of neuroblastoma. Based on these findings we selected plasma of blood donors with a high in-vitro cytotoxic activity against LA-N-1 neuroblastoma cells. Using these plasma preparations a phase I/II therapy study in children with relapsed neuroblastoma based on a complete plasma exchange has been instituted. 34 plasma exchange cycles have been performed in nine patients. This therapy has been found to be feasible in all patients. In three patients a transient minor tumor response has been observed. In one patient stable disease could be established for 3 years. In another patient, who has got ten therapy cycles, disease-free survival is maintained for 8 years without any further therapy. Conclusion: The response data in patients with relapsed high-risk neuroblastoma justify the further evaluation of this immunotherapeutic approach. For this purpose a standardized pharmaceutical product generated by screening and pooling the plasma of selected blood donors would be of benefit.
Authors:
Rudolf Erttmann
Related Documents :
215529 - Differences in ebv antibody titres of patients with nasopharyngeal carcinoma originatin...
21986769 - Bladder dysfunction and parkinsonism: current pathophysiological understanding and mana...
8168279 - Importance of serum anticardiolipin antibody levels in coronary heart disease.
19705119 - Autoantibodies in silicosis patients and in silica-exposed individuals.
7121659 - Antirifampicin antibodies in acute rifampicin-associated renal failure.
6327829 - Diagnosis of pertussis.
10973599 - Visual feedback has differential effects on reaching movements in parkinson's and alzhe...
18794219 - Evidence of increased motoneuron excitability in stroke patients without clinical spast...
7564789 - Role of thrombin in pulmonary fibrosis.
Publication Detail:
Type:  Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article     Date:  2008-04-15
Journal Detail:
Title:  Autoimmunity reviews     Volume:  7     ISSN:  1568-9972     ISO Abbreviation:  Autoimmun Rev     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-06-18     Completed Date:  2008-08-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101128967     Medline TA:  Autoimmun Rev     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  496-500     Citation Subset:  IM    
Affiliation:
Clinic of Pediatric Hematology and Oncology, University-Hospital, D-20246 Hamburg, Germany. erttmann@uke.uni-hamburg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Neoplasm / blood,  therapeutic use*
Child
Child, Preschool
Cytotoxicity, Immunologic
Humans
Immunoglobulin M / immunology,  therapeutic use
Neuroblastoma / drug therapy*,  immunology,  pathology
Rats
Chemical
Reg. No./Substance:
0/Antibodies, Neoplasm; 0/Immunoglobulin M

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?
Next Document:  Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.